Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13Rα2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results. SNO 2016.
Phase 2 Trial of SL-701, a Novel Immunotherapy Comprised of Synthetic Short Peptides Against GBM Targets IL-13Rα2, EphA2, and Survivin, in Adults With Second-Line Recurrent GBM: Interim Results
November 14, 2016